良性前列腺增大术后偶发前列腺癌危险因素的系统综述与荟萃分析
该研究系统检索MEDLINE、Embase和Web of Science,纳入25项研究共247,966例因良性前列腺增大接受手术的患者,其中6,748例发现偶发前列腺癌。荟萃分析显示,PSA升高、PSA密度>0.15 ng/mL/cc、年龄较大和BMI较高与偶发前列腺癌风险升高相关,而术前使用5α还原酶抑制剂与风险降低相关。
要点
- PSA密度>0.15 ng/mL/cc者偶发前列腺癌风险约升高3倍。
- 术前使用5α还原酶抑制剂与偶发前列腺癌风险降低相关。
- 前列腺体积、糖尿病和血脂异常与偶发前列腺癌风险无关联。
核心结论
- PSA升高、PSA密度高、年龄较大和BMI较高与良性前列腺增大术后偶发前列腺癌风险升高相关。
- 术前使用5α还原酶抑制剂与偶发前列腺癌风险降低相关。
- 上述发现可能有助于术前风险分层,识别需额外诊断评估或可避免评估的患者。
研究设计与样本
- 系统综述与荟萃分析,2025年1月检索MEDLINE、Embase和Web of Science。
- 纳入25项研究,共247,966例因良性前列腺增大接受手术的患者。
- 采用随机效应模型合并多变量分析中的校正OR及95%CI,并使用ROBINS-I工具评估偏倚风险。
主要发现
- 6,748例患者发现偶发前列腺癌,报告发生率范围为2.2%至49.6%。
- PSA升高:OR 1.03(95%CI 1.01-1.05,p=0.01)。
- PSA密度>0.15 ng/mL/cc:OR 3.02(95%CI 1.50-6.07,p=0.01)。
- 年龄较大:OR 1.05(95%CI 1.01-1.08,p=0.01);BMI较高:OR 1.10(95%CI 1.02-1.18,p=0.01)。
- 5α还原酶抑制剂使用:OR 0.53(95%CI 0.33-0.85,p=0.01);前列腺体积、糖尿病、血脂异常无关联。
关键数值与推荐
- PSA密度>0.15 ng/mL/cc与偶发前列腺癌风险升高相关(OR 3.02;95%CI 1.50-6.07)。
- 5α还原酶抑制剂使用与偶发前列腺癌风险降低相关(OR 0.53;95%CI 0.33-0.85)。
- 前列腺体积、糖尿病和血脂异常与偶发前列腺癌风险无显著关联。
临床怎么用
- 可结合PSA、PSA密度、年龄和BMI对良性前列腺增大手术患者进行术前偶发前列腺癌风险分层。
- 对高风险患者可考虑额外诊断评估,对低风险患者可考虑避免过度评估。
- 术前5α还原酶抑制剂使用史应纳入风险评估参考。
局限性
- 研究间存在异质性。
- 纳入研究多为回顾性设计。
- 关键变量报告不完整。
- 尚需进一步研究明确有临床意义偶发前列腺癌的预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Incidental prostate cancer (IPC) is not uncommon in patients undergoing surgery for benign prostate enlargement (BPE). However, the associated risk factors remain incompletely understood. This study aimed to evaluate potential clinical predictors of IPC. METHODS: A systematic search of MEDLINE, Embase, and Web of Science was conducted in January 2025 to identify studies assessing risk factors for IPC. Pairwise meta-analyses were performed using a random-effects model, pooling adjusted odds ratios (ORs) and 95% confidence intervals (CIs) from multivariable analyses. Risk of bias was evaluated using the ROBINS-I tool. (PROSPERO: CRD42024588776). RESULTS: Twenty-five studies comprising 247,966 patients were included. IPC was identified in 6,748 patients, with reported rates ranging from 2.2% to 49.6%. Significant risk factors for IPC included: Elevated PSA level (OR: 1.03; 95% CI: 1.01-1.05; p = 0.01), PSA density >0.15 ng/mL/cc (OR: 3.02; 95% CI: 1.50-6.07; p = 0.01), Older age (OR: 1.05; 95% CI: 1.01-1.08; p = 0.01), and Higher body mass index (BMI) (OR: 1.10; 95% CI: 1.02-1.18; p = 0.01). Prostate volume, diabetes, and dyslipidemia were not associated with IPC risk. Notably, use of 5-alpha reductase inhibitors (5-ARIs) was linked to a significantly reduced risk (OR: 0.53; 95% CI: 0.33-0.85; p = 0.01). Study limitations included heterogeneity across studies, retrospective designs, and incomplete reporting of key variables. CONCLUSIONS: Elevated PSA, high PSA density, older age, and increased BMI were associated with a higher risk of IPC in patients undergoing surgery for BPE. Conversely, preoperative use of 5-ARIs was associated with a reduced risk. These findings may support improved preoperative risk stratification and help identify patients in whom additional diagnostic evaluations could be considered or avoided. Further research is needed to better define predictors of clinically significant IPC.
引用
- Cormio A, Matsukawa A, Dematteis A, et al. Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2026. PMID: 41872314. doi:10.1038/s41391-026-01108-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。